Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non–small-cell lung cancer: A PRISMA-compliant meta-analysis

BACKGROUND: Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) have been developed for targeted therapies in non–small-cell lung cancer (NSCLC); moreover, some drug-related toxic reactions among cancer patients have been reported. A meta-analysis of randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Wen-wen, Zhang, Jin-jie, Zhou, Xiao-long, Song, Zheng, Wei, Chuan-mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571213/
https://www.ncbi.nlm.nih.gov/pubmed/31169681
http://dx.doi.org/10.1097/MD.0000000000015806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571213/
https://www.ncbi.nlm.nih.gov/pubmed/31169681
http://dx.doi.org/10.1097/MD.0000000000015806

Ejemplares similares